Nrx Pharmaceuticals Stock Current Ratio
| NRXP Stock | USD 3.02 0.03 1.00% |
NRX Pharmaceuticals fundamentals help investors to digest information that contributes to NRX Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of NRX Stock. The fundamental analysis module provides a way to measure NRX Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NRX Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 0.42 | 0.39 |
NRX | Current Ratio |
NRX Pharmaceuticals Company Current Ratio Analysis
NRX Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current NRX Pharmaceuticals Current Ratio | 4.58 X |
Most of NRX Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NRX Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NRX Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for NRX Pharmaceuticals is extremely important. It helps to project a fair market value of NRX Stock properly, considering its historical fundamentals such as Current Ratio. Since NRX Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NRX Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NRX Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
NRX Current Ratio Historical Pattern
Today, most investors in NRX Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various NRX Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of NRX Pharmaceuticals current ratio as a starting point in their analysis.
NRX Pharmaceuticals Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, NRX Pharmaceuticals has a Current Ratio of 4.58 times. This is 57.39% higher than that of the Biotechnology sector and 34.57% lower than that of the Health Care industry. The current ratio for all United States stocks is 112.04% lower than that of the firm.
NRX Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NRX Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NRX Pharmaceuticals could also be used in its relative valuation, which is a method of valuing NRX Pharmaceuticals by comparing valuation metrics of similar companies.NRX Pharmaceuticals is currently under evaluation in current ratio category among its peers.
NRX Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NRX Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NRX Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
NRX Fundamentals
| Return On Equity | -6.83 | ||||
| Return On Asset | -1.16 | ||||
| Current Valuation | 55.6 M | ||||
| Shares Outstanding | 16.92 M | ||||
| Shares Owned By Insiders | 23.56 % | ||||
| Shares Owned By Institutions | 6.00 % | ||||
| Number Of Shares Shorted | 1.21 M | ||||
| Price To Book | 2.90 X | ||||
| EBITDA | (30.02 M) | ||||
| Net Income | (30.15 M) | ||||
| Cash And Equivalents | 24.55 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 9.16 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.58 X | ||||
| Book Value Per Share | (1.42) X | ||||
| Cash Flow From Operations | (21.66 M) | ||||
| Short Ratio | 4.80 X | ||||
| Earnings Per Share | (2.11) X | ||||
| Target Price | 31.67 | ||||
| Beta | 1.27 | ||||
| Market Capitalization | 50.58 M | ||||
| Total Asset | 7.32 M | ||||
| Retained Earnings | (253.15 M) | ||||
| Working Capital | (12.16 M) | ||||
| Net Asset | 7.32 M |
About NRX Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NRX Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NRX Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NRX Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with NRX Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NRX Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NRX Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against NRX Stock
| 0.86 | NHC | National HealthCare | PairCorr |
| 0.81 | DERM | Journey Medical Corp Upward Rally | PairCorr |
| 0.69 | PNTG | Pennant Group | PairCorr |
| 0.68 | INNV | InnovAge Holding Corp Earnings Call This Week | PairCorr |
| 0.63 | ENSG | Ensign Group | PairCorr |
The ability to find closely correlated positions to NRX Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NRX Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NRX Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NRX Pharmaceuticals to buy it.
The correlation of NRX Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NRX Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NRX Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NRX Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.